ARM 210Alternative Names: S48168
Latest Information Update: 16 Dec 2015
At a glance
- Originator ARMGO Pharma
- Developer ARMGO Pharma; Servier
- Class Small molecules
- Mechanism of Action Ryanodine receptor calcium release channel modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Duchenne muscular dystrophy